# Table of Contents

**Volume 102, Issue 1: January 2017**

## Cover Figure

JAK2 and CALR mutant proteins in myeloproliferative neoplasms - image accompanying the review article on page 7 (Image created by www.somersault1824.com)

## Editorials

1. Circulating microRNAs: promising biomarkers in aplastic anemia  
   *Jonathan B. Bell et al.*

2. Risk stratification in myelofibrosis: the quest for simplification  
   *Laura C. Michaelis*

4. How “precise” is precision medicine in hematology?  
   *Carlo Gambacorti-Passerini and Rocco Piazza*

## Review Articles

### Leaders in Hematology - Mechanisms in Hematology

7. Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms  
   *Jacob Grinfeld, Jyoti Nangalia and Anthony R. Green et al.*

### Leaders in Hematology - Management in Hematology

18. From leeches to personalized medicine: evolving concepts in the management of polycythemia vera  
   *Alessandro M. Vannucchi*

30. The emerging role of immune checkpoint inhibition in malignant lymphoma  
   *Ida Hude et al.*

## Guideline Article

43. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome  
   *Monique C. Minnema et al.*

## Articles

### Blood Transfusion

52. Treatments for hematologic malignancies in contrast to those for solid cancers are associated with reduced red cell alloimmunization  
   *Dorothea Evers et al.*

### Iron Metabolism & Its Disorders

60. Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia  
   *Chloé Latour et al.*
Bone Marrow Failure

69  A plasma microRNA signature as a biomarker for acquired aplastic anemia
Kohei Hosokawa et al.

Myeloproliferative Disorders

79  An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis
Uri Rozovski et al.

85  Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group
Holly L. Geyer et al.

94  A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Yikas Gupta et al.

103  Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Alberto Alvarez-Larrán et al.

Acute Myeloid Leukemia

110  Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia
Betül Oran et al.

Acute Lymphoblastic Leukemia

118  ZNF384-related fusion genes consist of a subgroup with a characteristic immunophenotype in childhood B-cell precursor acute lymphoblastic leukemia
Shinsuke Hirabayashi et al.

130  Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis
Tobias Herold et al.

139  Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Sebastian Giebel et al.

Non-Hodgkin Lymphoma

150  Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association
Clémence Sarkozy et al.

Plasma Cell Disorders

160  High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation
Gordon Cook et al.

168  Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone
Ana-Alicia López-Iglesias et al.

Cell Therapy & Immunotherapy

176  The increase of the global donor inventory is of limited benefit to patients of non-Northwestern European descent
Suzanna M. van Walraven et al.

184  Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia
Mohamad Mohty et al.
Immunodeficiency

The immunophenotypic fingerprint of patients with primary antibody deficiencies is partially present in their asymptomatic first-degree relatives
Delfien J.A. Bogaert et al.

Letters to the Editor

Letters are available online only at www.hematologica.org/content/102/1.toc

e1 APOL1, α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia
Santosh L. Saraf et al.
http://www.hematologica.org/content/102/1/e1

e7 Myelodysplastic syndrome can propagate from the multipotent progenitor compartment
Kévin Rouault-Pierre et al.
http://www.hematologica.org/content/102/1/e7

e11 Genomic analysis of myeloproliferative neoplasms in chronic and acute phases
Frédéric Courtier et al.
http://www.hematologica.org/content/102/1/e11

e15 Absence of CALR mutations in JAK2-negative polycythemia
Aurélie Chauveau et al.
http://www.hematologica.org/content/102/1/e15

e17 CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells
Haiwei Lian et al.
http://www.hematologica.org/content/102/1/e17

e22 Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia
Paolo Strati et al.
http://www.hematologica.org/content/102/1/e22

e26 Impaired pulmonary endothelial barrier function in sickle cell mice
Nagavedi S. Umapathy et al.
http://www.hematologica.org/content/102/1/e26

Comments

Comments are available online only at www.hematologica.org/content/102/1.toc

e30 Gene panel sequencing in idiopathic erythrocytosis
François Girodon and Veronika Némethová
http://www.hematologica.org/content/102/1/e30

e31 Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic
Filip Rázga and Veronika Némethová
http://www.hematologica.org/content/102/1/e31